Evidence map›Paper›PMID 42232299›Full record

ArticleF1000Research2026

A guide to selecting high-performing antibodies for ARID2 (UniProt ID: Q68CP9) for use in western blot, immunoprecipitation, and immunofluorescence.

Vera Ruíz Moleón, Charles Alende, Maryam Fothouhi, Sara González Bolívar, Riham Ayoubi, Vincent Francis, Peter S McPherson, Carl Laflamme

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in F1000Research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Vera Ruíz MoleónDepartment of Neurology and Neurosurgery, Structural Genomics Consortium, The Montreal Neurological Institute, McGill University, Montreal, Québec, Canada.ORCID https://orcid.org/0000-0003-3728-3158
Charles AlendeDepartment of Neurology and Neurosurgery, Structural Genomics Consortium, The Montreal Neurological Institute, McGill University, Montreal, Québec, Canada.ORCID https://orcid.org/0009-0005-4611-6134
Maryam FothouhiDepartment of Neurology and Neurosurgery, Structural Genomics Consortium, The Montreal Neurological Institute, McGill University, Montreal, Québec, Canada.
Sara González BolívarDepartment of Neurology and Neurosurgery, Structural Genomics Consortium, The Montreal Neurological Institute, McGill University, Montreal, Québec, Canada.ORCID https://orcid.org/0000-0002-4299-8281
Riham AyoubiDepartment of Neurology and Neurosurgery, Structural Genomics Consortium, The Montreal Neurological Institute, McGill University, Montreal, Québec, Canada.
Vincent FrancisDepartment of Neurology and Neurosurgery, Structural Genomics Consortium, The Montreal Neurological Institute, McGill University, Montreal, Québec, Canada.ORCID https://orcid.org/0009-0000-7535-8718
Peter S McPhersonDepartment of Neurology and Neurosurgery, Structural Genomics Consortium, The Montreal Neurological Institute, McGill University, Montreal, Québec, Canada.
Carl LaflammeDepartment of Neurology and Neurosurgery, Structural Genomics Consortium, The Montreal Neurological Institute, McGill University, Montreal, Québec, Canada.ORCID https://orcid.org/0000-0001-5906-025X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The AT-rich interactive domain-containing protein 2 (ARID2) is a core component of the chromatin-remodeling complex that regulates transcription by modulating nucleosome positioning. Here we have characterized six ARID2 commercial antibodies for western blot, immunoprecipitation, and immunofluorescence using a standardized experimental protocol based on comparing read-outs in knockout cell lines and isogenic parental controls. These studies are part of a larger, collaborative initiative seeking to address antibody reproducibility issues by characterizing commercially available antibodies for human proteins and publishing the results openly as a resource for the scientific community. While the use of antibodies and protocols vary between laboratories, we encourage readers to use this report as a guide to select the most appropriate antibodies for their specific needs.

Indexed as

AntibodiesBlotting, WesternDNA-Binding ProteinsFluorescent Antibody TechniqueImmunoprecipitationTranscription FactorsHumansAntibodiesDNA-Binding ProteinsTranscription Factorsantibody characterizationantibody validationARID2AT-Rich Interaction Domain 2immunofluorescenceimmunoprecipitationQ68CP9western blot

Identifiers

PMID42232299
PMCPMC13224947

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.